Iwasaki Hiroyuki, Toda Soji, Murayama Daisuke, Kato Shin, Matsui Ai
Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
Mol Clin Oncol. 2021 Feb;14(2):32. doi: 10.3892/mco.2020.2194. Epub 2020 Dec 17.
The present study retrospectively reviewed the treatment courses and results of patients with follicular thyroid tumors, including carcinomas. In the 5 year study period from April 2015 to March 2020, 797 patients with differentiated thyroid carcinoma and 128 patients with follicular tumors (FTs) received surgery or treatment for distant metastases and recurrence at the Kanagawa Cancer Center (Japan). Of these patients, 73 that were diagnosed with follicular thyroid carcinoma (FTC) were included in the present study. An algorithm used for the application of treatment strategies was assessed. The aim of the present study was to examine patients with FT or FTC who were treated at the Kanagawa Cancer Center to devise appropriate treatment strategies and to evaluate the various treatment outcomes of FTC. Pre-diagnostic serum thyroglobulin and thyroid stimulating hormone levels, follow-up and overall survival (OS) were investigated in the present study. The results revealed that OS was significantly increased in patients with minimally invasive follicular thyroid cancer (MIFTC) compared with widely invasive follicular thyroid cancer (WIFTC) (log-rank test, P=0.017). Additionally, OS was significantly higher in patients without distant metastasis at the first consultation compared with those initially diagnosed with distant metastasis (log-rank test, P=0.023). Although all patients without distant metastasis at the first consultation and those with MIFTC are alive, the 10-year survival rates were 75.3% for patients with WIFTC and 75.6% for those with distant metastasis at the first consultation. The results of the present study suggested that the prognosis of WIFTC was the worst among patients with FTC and distant metastasis, and that total thyroidectomy surgery and radioactive iodine treatment are essential. Additionally, if the disease progresses, prompt inclusion of tyrosine kinase inhibitor therapy is necessary.
本研究回顾性分析了包括癌在内的滤泡性甲状腺肿瘤患者的治疗过程及结果。在2015年4月至2020年3月的5年研究期间,797例分化型甲状腺癌患者和128例滤泡性肿瘤(FTs)患者在日本神奈川县癌症中心接受了手术或远处转移及复发的治疗。在这些患者中,本研究纳入了73例被诊断为滤泡性甲状腺癌(FTC)的患者。评估了一种用于应用治疗策略的算法。本研究的目的是检查在神奈川县癌症中心接受治疗的FT或FTC患者,以制定合适的治疗策略并评估FTC的各种治疗结果。本研究调查了诊断前血清甲状腺球蛋白和促甲状腺激素水平、随访情况及总生存期(OS)。结果显示,与广泛侵袭性滤泡性甲状腺癌(WIFTC)相比,微侵袭性滤泡性甲状腺癌(MIFTC)患者的OS显著延长(对数秩检验,P=0.017)。此外,初诊时无远处转移的患者的OS显著高于最初诊断为有远处转移的患者(对数秩检验,P=0.023)。虽然所有初诊时无远处转移的患者和MIFTC患者均存活,但WIFTC患者的10年生存率为75.3%,初诊时有远处转移的患者为75.6%。本研究结果表明,在FTC和远处转移患者中,WIFTC的预后最差,全甲状腺切除术和放射性碘治疗至关重要。此外,如果疾病进展,必须及时采用酪氨酸激酶抑制剂治疗。